Figure 1. Research Method Flow Chart 12
Figure 2. Breakdown of Primary Research 14
Figure 3. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 4. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2019-2030 18
Figure 5. Global Influenza Treatment Market, 2019-2030, $ mn 20
Figure 6. Impact of COVID-19 on Business 21
Figure 7. Primary Drivers and Impact Factors of Global Influenza Treatment Market 23
Figure 8. GDP per capita in the World, 1960-2018, $ thousand 26
Figure 9. Forecast of Middle-class Population by Region, 2015-2030, million 26
Figure 10. Primary Restraints and Impact Factors of Global Influenza Treatment Market 27
Figure 11. Investment Opportunity Analysis 31
Figure 12. Porter’s Fiver Forces Analysis of Global Influenza Treatment Market 34
Figure 13. Breakdown of Global Influenza Treatment Market by Product Type, 2019-2030, % of Revenue 38
Figure 14. Global Addressable Market Cap in 2020-2030 by Product Type, Value ($ mn) and Share (%) 39
Figure 15. Global Influenza Treatment Market: Oseltamivir Phosphate, 2019-2030, $ mn 40
Figure 16. Global Influenza Treatment Market: Baloxavir Marboxil, 2019-2030, $ mn 41
Figure 17. Global Influenza Treatment Market: Peramivir, 2019-2030, $ mn 42
Figure 18. Global Influenza Treatment Market: Zanamivir, 2019-2030, $ mn 43
Figure 19. Global Influenza Treatment Market: Other Drugs, 2019-2030, $ mn 44
Figure 20. Breakdown of Global Influenza Treatment Market by Influenza Type, 2019-2030, % of Sales Revenue 45
Figure 21. Global Addressable Market Cap in 2020-2030 by Influenza Type, Value ($ mn) and Share (%) 46
Figure 22. Global Influenza Treatment Market: Influenza A, 2019-2030, $ mn 47
Figure 23. Global Influenza Treatment Market: Influenza B, 2019-2030, $ mn 48
Figure 24. Global Influenza Treatment Market: Influenza C, 2019-2030, $ mn 49
Figure 25. Breakdown of Global Influenza Treatment Market by Administration Route, 2019-2030, % of Sales Revenue 50
Figure 26. Global Addressable Market Cap in 2020-2030 by Administration Route, Value ($ mn) and Share (%) 51
Figure 27. Global Influenza Treatment Market: Oral Administration, 2019-2030, $ mn 52
Figure 28. Global Influenza Treatment Market: Other Administration Routes, 2019-2030, $ mn 53
Figure 29. Breakdown of Global Influenza Treatment Market by Distribution Channel, 2019-2030, % of Revenue 54
Figure 30. Global Addressable Market Cap in 2020-2030 by Distribution Channel, Value ($ mn) and Share (%) 55
Figure 31. Global Influenza Treatment Market: Retail Pharmacy, 2019-2030, $ mn 56
Figure 32. Global Influenza Treatment Market: Hospital Pharmacy, 2019-2030, $ mn 57
Figure 33. Global Influenza Treatment Market: Clinics, 2019-2030, $ mn 58
Figure 34. Global Influenza Treatment Market: Online Stores, 2019-2030, $ mn 59
Figure 35. Global Market Snapshot by Region 60
Figure 36. Geographic Spread of Worldwide Influenza Treatment Market, 2019-2030, % of Sales Revenue 61
Figure 37. Global Addressable Market Cap in 2020-2030 by Region, Value ($ mn) and Share (%) 62
Figure 38. Health Spending as a Share of GDP by Country, 2015 and 2030 64
Figure 39. North American Influenza Treatment Market, 2019-2030, $ mn 67
Figure 40. Breakdown of North America Influenza Treatment Market by Country, 2019 and 2030, % of Revenue 68
Figure 41. Contribution to North America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 69
Figure 42. U.S. Influenza Treatment Market, 2019-2030, $ mn 71
Figure 43. Canada Influenza Treatment Market, 2019-2030, $ mn 74
Figure 44. Influenza Treatment Market in Mexico, 2015-2030, $ mn 76
Figure 45. European Influenza Treatment Market, 2019-2030, $ mn 79
Figure 46. Breakdown of European Influenza Treatment Market by Country, 2019 and 2030, % of Revenue 80
Figure 47. Contribution to Europe 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 81
Figure 48. Influenza Treatment Market in Germany, 2019-2030, $ mn 82
Figure 49. Influenza Treatment Market in UK, 2019-2030, $ mn 84
Figure 50. Influenza Treatment Market in France, 2019-2030, $ mn 86
Figure 51. Influenza Treatment Market in Spain, 2019-2030, $ mn 88
Figure 52. Influenza Treatment Market in Italy, 2019-2030, $ mn 90
Figure 53. Influenza Treatment Market in Russia, 2019-2030, $ mn 92
Figure 54. Influenza Treatment Market in Rest of Europe, 2019-2030, $ mn 94
Figure 55. Asia-Pacific Influenza Treatment Market, 2019-2030, $ mn 97
Figure 56. Breakdown of APAC Influenza Treatment Market by Country, 2019 and 2030, % of Revenue 97
Figure 57. Contribution to APAC 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 99
Figure 58. Influenza Treatment Market in Japan, 2019-2030, $ mn 101
Figure 59. Influenza Treatment Market in China, 2019-2030, $ mn 103
Figure 60. Influenza Treatment Market in Australia, 2019-2030, $ mn 105
Figure 61. Influenza Treatment Market in India, 2019-2030, $ mn 107
Figure 62. Influenza Treatment Market in South Korea, 2019-2030, $ mn 109
Figure 63. Influenza Treatment Market in Rest of APAC, 2019-2030, $ mn 111
Figure 64. South America Influenza Treatment Market, 2019-2030, $ mn 114
Figure 65. Breakdown of South America Influenza Treatment Market by Country, 2019 and 2030, % of Revenue 114
Figure 66. Contribution to South America 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 115
Figure 67. Influenza Treatment Market in Argentina, 2019-2030, $ mn 116
Figure 68. Influenza Treatment Market in Brazil, 2019-2030, $ mn 118
Figure 69. Influenza Treatment Market in Chile, 2019-2030, $ mn 120
Figure 70. Influenza Treatment Market in Rest of South America, 2019-2030, $ mn 122
Figure 71. Influenza Treatment Market in Middle East and Africa (MEA), 2019-2030, $ mn 124
Figure 72. Breakdown of MEA Influenza Treatment Market by Country, 2019 and 2030, % of Revenue 124
Figure 73. Contribution to MEA 2020-2030 Cumulative Revenue by Country, Value ($ mn) and Share (%) 125
Figure 74. Influenza Treatment Market in UAE, 2019-2030, $ mn 126
Figure 75. Influenza Treatment Market in Saudi Arabia, 2019-2030, $ mn 128
Figure 76. Influenza Treatment Market in South Africa, 2019-2030, $ mn 130
Figure 77. Growth Stage of Global Influenza Treatment Industry over the Forecast Period 133
Global influenza treatment market will reach $1,371.0 billion by 2030, growing by 3.8% annually over 2020-2030 driven by rising incidences of influenza, growing awareness and need for new drugs and treatment across the globe. Highlighted with 83 tables and 77 figures, this 156-page report “Global Influenza Treatment Market 2020-2030 by Product Type, Influenza Type, Administration Route, Distribution Channel, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global influenza treatment market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.) In-depth qualitative analyses include identification and investigation of the following aspects: • Market Structure • Growth Drivers • Restraints and Challenges • Emerging Product Trends & Market Opportunities • Porter’s Fiver Forces The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global influenza treatment market in every aspect of the classification from perspectives of Product Type, Influenza Type, Administration Route, Distribution Channel, and Region. Based on Product Type, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oseltamivir Phosphate • Baloxavir Marboxil • Peramivir • Zanamivir • Other Drugs Based on Influenza Type, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Influenza A • Influenza B • Influenza C Based on Administration Route, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Oral Administration • Other Administration Routes Based on Distribution Channel, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. • Retail Pharmacy • Hospital Pharmacy • Clinics • Online Stores Geographically, the following regions together with the listed national/local markets are fully investigated: • APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka) • Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania) • North America (U.S., Canada, and Mexico) • South America (Brazil, Chile, Argentina, Rest of South America) • RoW (Saudi Arabia, UAE, South Africa) For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Product Type, Administration Route, and Distribution Channel over the forecast years are also included. The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players. Specifically, potential risks associated with investing in global influenza treatment market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions. Key Players (this may not be a complete list and extra companies can be added upon request): AstraZeneca Plc BioCryst Pharmaceuticals Inc. Biondvax Daiichi Sankyo Company F. Hoffmann-La Roche Ltd. (Genentech USA, Inc.) GlaxoSmithKline Plc Mylan N.V Natco Pharma Limited Novartis AG Sanofi Seqirus Teva Pharmaceutical Industries Limited (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)
Read More